Worse Survival Noted for Patients With Cancer Treated in States With Lower Medicaid Eligibility Limits


Based on outcomes from a study involving patients with cancer, Medicaid may benefit from expansion in certain areas where eligibility limits hinder adequate coverage.

Long-term survival was shorter in patients with cancer who were from states where Medicaid income eligibility limits were lower, according to research presented during a media briefing leading up to the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

“Policies to increase Medicaid income eligibility limits such as Medicaid expansion may help improve survival following cancer diagnosis,” Jingxuan Zhao, MPH, associate scientist with the American Cancer Society, said during the webcast.

Income eligibility limits for Medicaid varies substantially by state for non-elderly patients, according to the presentation. For example, the federal poverty line for a family of 4 in 2009 was $22,050. The Medicaid eligibility limit was 27% of the federal poverty line in Texas, whereas this limit was 150% for New York.

With this study, investigators aimed to assess the associations between state Medicaid income eligibility limits and long-term survival in patients with newly diagnosed cancer. This was analyzed with data from an estimated 1.5 million adults from the National Cancer Database aged 18 to 64 years who were newly diagnosed with 17 common cancers between 2010 and 2013. Patients were followed up through the end of 2017 for up to 8 years.

State Medicaid income eligibility limits were categorized as less than 50% of the federal poverty line, between 51% and 137% of the federal poverty line, and greater than 138% of the federal poverty line.

When patients with all cancer types were combined, patients who lived in states with the lowest Medicaid income eligibility limits had the worst survival rates compared with those who lived in states with high limits. This was seen for patients with stages I/II cancers and in those with stages III/IV cancers.

Similar findings were observed when data were categorized by cancer type. For example, compared with states with eligibility limits greater than 138%, women with stage I/II breast cancer in states with a limit less than 50% (adjusted HR, 1.31; 95% CI, 1.18-1.46) and limits between 51% and 137% (adjusted HR, 1.17; 95% CI, 1.06-1.3) had worse long-term survival. This was also seen in women with stage III/IV breast cancer (adjusted HR for less than 50%, 1.21; 95% CI, 1.1-1.33; adjusted HR for 51% to 137%, 1.13; 95% CI, 1.03-1.23).

The investigators also observed similar findings for other common cancers including prostate, colorectal, and non–small cell lung cancers.

“[These findings are] particularly relevant … since there [are] such variable limits among states regarding Medicaid expansion with the [Affordable Care Act],” Lori J. Pierce, MD, FASTRO, FASCO, radiation oncologist, professor, and Vice Provost for Academic and Faculty Affairs at the University of Michigan in Ann Arbor and director of the Michigan Radiation Oncology Quality Consortium, said during the discussion after the presentation. “I think these data can be used to encourage those states who have chosen not to expand Medicaid coverage to strongly reconsider because people who are uninsured are very likely to forego screening, so you miss the detection of early lesions where cure would be far more likely. Those who are uninsured are unlikely to receive cancer care. And for those who are able to start cancer treatment, they’re unlikely to complete their cancer care. Equity of care is very, very critical.”


Zhao J, et al. Association of State Medicaid Income Eligibility Limits and Long-Term Survival After Cancer Diagnosis in the United States. Presented at: 2021 ASCO Annual Meeting; June 4-8, 2021; Virtual. Abstract 6512.

Related Videos
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.